ReviewFrontiers in immunology2026
Microscopic messengers: roles and prospects of extracellular vesicles in hepatitis B and C.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles (EVs) are important mediators of intercellular communication in hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. EVs released from infected hepatocytes can carry viral nucleic acids, proteins, and regulatory non-coding RNAs to immune and nonimmune cells, thereby influencing viral dissemination, immune regulation, and disease progression. In particular, EV-associated cargos modulate antiviral immunity by affecting interferon signaling, natural killer cell function, cytokine production, immune checkpoint pathways, and T-cell exhaustion. These effects may promote viral persistence and immune evasion, although some EV populations can also enhance innate antiviral responses, indicating context-dependent dual roles. EVs also contribute to fibrosis and hepatocarcinogenesis by regulating hepatic stellate cell activation, inflammatory signaling, and tumor microenvironment remodeling. In addition, EV-derived RNAs and proteins show potential as noninvasive biomarkers and therapeutic targets. This review summarizes current evidence on EVs in HBV and HCV infection, with emphasis on immune regulation, viral persistence, disease progression, and translational prospects, while also discussing key challenges such as EV heterogeneity and co-isolation with viral particles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.